“…3 TAVR is a class I indication for AVR in prohibitive-risk patients and is approved for intermediate-risk patients, [4][5][6] with consideration now under way for suitability in a low-risk patient population. 7,8 Increased attention is focused on patient outcomes and improving quality of care. Specific metrics of interest in the perioperative setting include utilization of blood products, need for intensive care unit admission, overall length of stay, and hospital readmission.…”